SCHEMBL1785318

SCHEMBL1785318

Cc1nc(NC(=O)NCc2ccncc2)sc1-c1ccc(S(C)(=O)=O)c(F)c1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 12/20 0.67
PIK3CG P48736 12/20 0.67
PIK3CA P42336 11/20 0.67
PIK3CB P42338 9/20 0.67
CLK1 P49759 1/20 0.61
CLK2 P49760 1/20 0.61
PI4KB Q9UBF8 1/20 0.61
NAMPT P43490 3/20 0.47
ROCK2 O75116 5/20 0.44
ROCK1 Q13464 5/20 0.44
SGK1 O00141 1/20 0.42
AKT1 P31749 1/20 0.42
GSK3B P49841 1/20 0.42
LIMK1 P53667 1/20 0.42
TNK2 Q07912 1/20 0.42
DMPK Q09013 1/20 0.42
MYLK Q15746 1/20 0.42
CDC42BPA Q5VT25 1/20 0.42
PIK3C3 Q8NEB9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48665 0.87 PIK3CD (0.56) PIK3CDPIK3CGPIK3CAPIK3CBCLK1
SCHEMBL48455 0.86 PIK3CD (0.75) PIK3CDPIK3CGPIK3CAPIK3CBCLK1
SCHEMBL48530 0.85 PIK3CD (0.65) PIK3CDPIK3CGPIK3CAPIK3CBCLK1
SCHEMBL48832 0.85 PIK3CD (0.75) PIK3CDPIK3CGPIK3CAPIK3CBCLK1
SCHEMBL1788182 0.84 PIK3CD (0.77) PIK3CDPIK3CGPIK3CAPIK3CBCLK1
SCHEMBL12363422 0.83 PIK3CD (0.80) PIK3CDPIK3CGPIK3CAPIK3CBCLK1
SCHEMBL5785803 0.83 PIK3CG (0.70) PIK3CDPIK3CGPIK3CAPIK3CBCLK1
SCHEMBL49031 0.83 PIK3CD (0.73) PIK3CDPIK3CGPIK3CAPIK3CBCLK1
SCHEMBL1786751 0.83 PIK3CG (0.65) PIK3CDPIK3CGPIK3CAPIK3CBCLK1
SCHEMBL48639 0.83 PIK3CG (0.65) PIK3CDPIK3CGPIK3CAPIK3CBCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases NOVARTIS AG (CH) 2008-11-13 US claimed
US-20110124693-A1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2011-05-26 US disclosed
US-20110124624-A1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2011-05-26 US disclosed
US-7902375-B2 Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis NOVARTIS AG (CH) 2011-03-08 US disclosed
EP-1689391-B1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES NOVARTIS AG (CH) 2009-04-22 EP disclosed
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases NOVARTIS AG (CH) 2008-11-13 US disclosed
EP-1689391-A2 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES Novartis AG (CH) 2006-08-16 EP disclosed
WO-2005021519-A2 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES NOVARTIS AG (CH) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124693-A1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES PIK3CA, JAK2, JAK1 PIK3CD 12/4885PIK3CG 6/4885PIK3CA 1/4885
US-20110124624-A1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES PIK3CA, JAK2, JAK3 PIK3CD 10/4885PIK3CG 6/4885PIK3CA 1/4885
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases PI4KA, IP6K3, PHOSPHO1 PIK3CD 26/4885PIK3CG 23/4885PIK3CA 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.